{
    "doi": "https://doi.org/10.1182/blood-2018-99-110210",
    "article_title": "Percentage of Erythroid Cells in Bone Marrow at Diagnosis As a New Prognostic Factor in Patients with Myelodysplastic Syndrome ",
    "article_date": "November 29, 2018",
    "session_type": "637. Myelodysplastic Syndromes\u2014Clinical Studies: Poster III",
    "abstract_text": "Introduction Risk assessment is essential for guiding therapy in patients with myelodysplastic syndromes (MDS). Currently, the most widely used prognostic scoring models are the International Prognostic Scoring System (IPSS) and the revised IPSS (IPSS-R). The prognostic relevance of the percentage of erythroid precursors (EP) in bone marrow (BM) and its relationship with other biological characteristics has been poorly studied, although it has been proposed that a very low percentage of EP in BM may represent a cohort of patients with potentially adverse outcome. Our main aim was to analyze the biological and clinical features of MDS patients according to the percentage of EP in BM at diagnosis and evaluate its prognostic value on survival. Patients and Methods Data from 4,791 de novo MDS patients from the MDS Spanish Registry with available cytogenetics were collected. All patients included were diagnosed based on the 2008 WHO criteria and risk stratification was performed following the IPSS-R. Patients were distributed, according to the percentage of EP in BM, into three groups: less than 15% (EP49%). Proportions were compared by the Chi-square test. Survival curves were constructed by Kaplan-Meier method and differences between curves were evaluated by log rank tests. Multivariable analysis of survival was performed using Cox's proportional hazards regression model. P-values <0.05 were considered as statistically significant. All statistical analyses were performed by the R software. Results The 4,791 cases were grouped according to the percentage of erythroid cells in BM at diagnosis. In Table 1 are displayed the clinical and biological characteristics of the patients in the whole series and in the three groups based on the EP percentage in BM. The group with EP49% group presented higher rates of patients with refractory anemia with ring sideroblasts (RARS), lower number of PB and BM blasts, and more frequent high-risk cytogenetics. Conversely, the intermediate EP group with EP 15-49% showed less number of cytopenias, higher frequency of good-prognosis cytogenetics, and lower percentage of patients in higher-risk IPSS-R categories. Survival analyses confirmed that age, blast percentage in PB and BM, and IPSS-R cytogenetics are significantly associated with worse survival. A striking difference in survival within groups according to percentage of EP was also found, recognizing EP percentage as an independent risk factor for survival of MDS patients in multivariate analysis. Patients with EP<15% in BM experienced a significantly shorter OS (median, 28 months) in both univariable (P<0.0001) and multivariable analysis (P<0.0001) ( Table 2 and Figure 1 ). The best survival was found for patients with EP 15-49% with a median survival of 58 months. The group with EP>50% in BM had also worse survival than the intermediate group, showing a median survival of 47 months (hazard ratio, 0.79; 95% CI, 0.67 to 0.93; P < 0.005). Conclusions Our study proves the prognostic impact of the percentage of erythroid precursors in bone marrow in MDS patients, providing evidence that the presence of EP <15% in BM is an independent risk factor for survival. View large Download slide View large Download slide  Close modal Disclosures D\u00edez-Campelo: Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau.",
    "topics": [
        "bone marrow",
        "erythroid cells",
        "myelodysplastic syndrome",
        "prognostic factors",
        "prostatic hypertrophy risk score",
        "cytopenia",
        "refractory anemia with sideroblasts",
        "refractory anemias",
        "signs and symptoms",
        "kaplan-meier survival curve"
    ],
    "author_names": [
        "Ana Villalba",
        "Leonor Senent",
        "Esther Alonso",
        "Elvira Mora",
        "Teresa Bernal Del Castillo, MD PhD",
        "Fernando Ramos",
        "Arenillas Leonor, MD PhD",
        "Ana Vicente",
        "Teresa Orero",
        "Mar Tormo, MD PhD",
        "Teresa Ardanaz",
        "Victor Marco",
        "Maria D\u00edez-Campelo",
        "Andres Jerez",
        "Julia Montoro",
        "Beatriz Arrizabalaga, MD PhD",
        "Rafael Lluch, Dr.",
        "Raquel de Paz",
        "Patricia Font",
        "Ignacio Lorenzo",
        "Guillermo Sanz"
    ],
    "author_dict_list": [
        {
            "author_name": "Ana Villalba",
            "author_affiliations": [
                "Hematology Department, Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Leonor Senent",
            "author_affiliations": [
                "Hematology Department, Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain ",
                "CIBERONC, Madrid, Spain ",
                "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Valencia, Spain "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Esther Alonso",
            "author_affiliations": [
                "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Valencia, Spain ",
                "Pathology Department, Hospital Universitari de Bellvitge, Barcelona, Spain "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Elvira Mora",
            "author_affiliations": [
                "Hematology Department, Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain ",
                "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Valencia, Spain "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Teresa Bernal Del Castillo, MD PhD",
            "author_affiliations": [
                "Hospital Universitario Central de Asturias, Oviedo, Spain ",
                "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Oviedo, Spain "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Fernando Ramos",
            "author_affiliations": [
                "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Valencia, Spain ",
                "Hospital Universitario de Le\u00f3n, Le\u00f3n, Sri Lanka "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Arenillas Leonor, MD PhD",
            "author_affiliations": [
                "Laboratorio Citolog\u00eda Hematol\u00f3gica. Servicio Patolog\u00eda, GRETNHE, IMIM Hospital del Mar Research Institute, Barcelona, Spain ",
                "Laboratoris de Citologia Hematol\u00f2gica i Citogen\u00e8tica, servei de Patologia. GRETNHE- Institut Hospital del Mar d'Investigacions M\u00e8diques (IMIM), Barcelona, Spain "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ana Vicente",
            "author_affiliations": [
                "Hematology Department, Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain ",
                "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Valencia, Spain "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Teresa Orero",
            "author_affiliations": [
                "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Valencia, Spain ",
                "Hospital General Universitario de Valencia, Valencia, Spain "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mar Tormo, MD PhD",
            "author_affiliations": [
                "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Valencia, Spain ",
                "Hematology Department, Hospital Cl\u00ednico Universitario, Instituto de investigacion INCLIVA, Valencia, Valencia, Spain "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Teresa Ardanaz",
            "author_affiliations": [
                "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Valencia, Spain ",
                "Hospital Universitario Txagorritxu, Vitoria, Spain "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Victor Marco",
            "author_affiliations": [
                "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Valencia, Spain ",
                "Hospital Arnau de Vilanova, Lleida, Spain "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria D\u00edez-Campelo",
            "author_affiliations": [
                "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Valencia, Spain ",
                "Hematology Department, Hospital Cl\u00ednico Universitario de Salamanca (CAUSA/IBSAL), Salamanca, Spain "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andres Jerez",
            "author_affiliations": [
                "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Valencia, Spain ",
                "Hematology and Medical Oncology Department, Hospital Morales Meseguer, IMIB, Murcia, Spain, MURCIA, Spain "
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Julia Montoro",
            "author_affiliations": [
                "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Valencia, Spain ",
                "Department of hematology, University Hospital Vall d\u00b4Hebron, Barcelona, Spain, Barcelona, Spain "
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Beatriz Arrizabalaga, MD PhD",
            "author_affiliations": [
                "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Valencia, Spain ",
                "Hospital Universitario de Cruces, Baracaldo, Spain "
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Rafael Lluch, Dr.",
            "author_affiliations": [
                "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Valencia, Spain ",
                "Hospital La Ribera, Alzira, Spain "
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Raquel de Paz",
            "author_affiliations": [
                "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Valencia, Spain ",
                "Hospital Universitario La Paz, Madrid, Spain "
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Patricia Font",
            "author_affiliations": [
                "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Valencia, Spain ",
                "Hospital Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ignacio Lorenzo",
            "author_affiliations": [
                "Hematology Department, Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain ",
                "CIBERONC, Madrid, Spain "
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Guillermo Sanz",
            "author_affiliations": [
                "Hematology Department, Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain ",
                "CIBERONC, Madrid, Spain ",
                "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Valencia, Spain "
            ],
            "author_rank": 21,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-14T12:58:11",
    "is_scraped": "1"
}